Shots:
- AstraZeneca reported full results from the P-III OBERON and TITANIA studies, showing that tozorakimab 300 mg Q4W reduced moderate-to-severe COPD exacerbations versus PBO in pts. receiving inhaled standard of care
- In the primary population of former smokers, tozorakimab reduced exacerbations by 29% in OBERON and 34% in TITANIA, while reductions in the overall population of current and former smokers were 30% and 29%, respectively; pooled analyses showed reductions across blood eosinophil thresholds
- Tozorakimab’s BLA received US FDA Priority Review for add-on COPD maintenance treatment, with a PDUFA decision expected in Q1 2027; Phase III OBERON and TITANIA results were presented at ERS’26 and published in the NEJM
S
Ref: AstraZeneca | Image: AstraZeneca | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
